T1	Participants 96 150	in patients with newly diagnosed or recurrent epilepsy
T2	Participants 228 268	patients with untreated, newly diagnosed
T3	Participants 388 425	Patients received 24 weeks' treatment
T4	Participants 830 854	More patients on CBZ 600
T5	Participants 1056 1097	a greater proportion of the CBZ 600 group
T6	Participants 1399 1425	patients on CBZ 600 (5.1%)
